fremanezumab (Ajovy)
Jump to navigation
Jump to search
Indications
- prevention of chronic migraine[1][2] (FDA-approved 9/18[3])
- benefit for patients with comorbid depression &/or anxiety[4]
* clinical utility not established[1]
* 1.3-1.5-day reduction in mean number of monthly migraine days[2]
Dosage
- 675 mg SQ at baseline & 225 mg every 4 weeks
Adverse effects
- injection site reactions (common)
Mechanism of action
- humanized monoclonal antibody targeting CGRP (calcitonin gene-related peptide)
More general terms
References
- ↑ 1.0 1.1 1.2 Silberstein SD, Dodick DW, Bigal M et al Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med 2017; 377:2113-2122. Nov 30, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29171818 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1709038
- ↑ 2.0 2.1 2.2 Dodick DW, Silberstein SD, Bigal M et al Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine. A Randomized Clinical Trial. JAMA. 2018;319(19):1999-2008. May 15, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29800211 https://jamanetwork.com/journals/jama/fullarticle/2681193
- ↑ 3.0 3.1 NEJM JWatch Editors New Migraine Prevention Treatment Approved Physician's First Watch, Sept 17, 2018 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
Brauser D FDA Approves Fremanezumab (Ajovy) for Migraine Prevention. Medscape - Sep 17, 2018 https://www.medscape.com/viewarticle/902071 - ↑ 4.0 4.1 Monaco K Migraine Drug Shows Benefit for Those With Comorbid Depression, Anxiety. MedPage Today November 1, 2021 https://www.medpagetoday.com/meetingcoverage/psychcongress/95365